8-K: Sonnet BioTherapeutics Highlights SON-1010 Potential at AACR IO Conference

Sonnet BioTherapeutics presented data at the AACR IO Conference showcasing the potential of SON-1010, a novel immunotherapeutic, as a monotherapy or in combination to improve solid tumor treatment.

Summary

• Sonnet BioTherapeutics announced the presentation of data at the 2025 American Association for Cancer Research (AACR) IO Conference.
• The presentation focused on SON-1010 and its potential to improve the treatment of solid tumors.
• SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12) configured using genetic fusion to the FHAB platform.
• The FHAB platform enhances targeting to the tumor microenvironment (TME) and prolongs retention in the tumor.
• The company's Fully Human Albumin Binding (FHAB) platform has been compiled with existing data and presented in a poster for the first time.
• In December 2024, the Company disclosed clinical benefit in 48% of patients, including a partial response at the highest dose in a patient with clear cell sarcoma.
• SON-1010 is being evaluated in a Phase 1b/2a dose-escalation study in combination with atezolizumab for platinum-resistant ovarian cancer (PROC).
• Another trial evaluating dose escalation of SON-1210 (IL12-FHAB-IL15) in patients with metastatic pancreatic cancer is expected to begin later this calendar year.
• An update on safety at the MTD in the PROC trial is expected in Q1 calendar year 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive, reflecting the presentation of data at a major conference and ongoing clinical trials. However, the forward-looking statements and inherent risks in drug development temper the overall optimism.

Positives

• The FHAB platform has demonstrated the potential to safely extend the half-life of cytokines and deliver them to the tumor.
• SON-1010 and SON-1210 address safety and tolerability factors that have traditionally hindered the use of therapeutic cytokines.
• SON-1010 has shown clinical benefit in 48% of patients in a monotherapy trial.
• The company is exploring multiple combination therapies with SON-1010 to improve outcomes in various cancers.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those expressed or implied in the forward-looking statements.
• The company's filings with the SEC contain a list of factors that could cause actual results to differ.

Future Outlook

The company anticipates announcing additional data from ongoing studies evaluating the SON-1010 platform in 2025 and expects to begin a trial evaluating SON-1210 in patients with metastatic pancreatic cancer later this calendar year.

Management Comments

• 'We are pleased to share the compilation of data in this poster presentation and look forward to announcing additional data from our ongoing studies evaluating our SON-1010 platform in 2025,' commented Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet.

Industry Context

The announcement highlights Sonnet's efforts to improve cancer immunotherapy by addressing limitations of recombinant interleukins, such as inefficient tumor targeting and off-target toxicity, through its FHAB platform.

Comparison to Industry Standards

• The document does not contain enough information to make a comparison to industry standards.
• More information is needed about the specific results of the clinical trials and how they compare to other immunotherapies in development.

Stakeholder Impact

• Positive impact on shareholders due to potential advancement of drug candidates.
• Potential benefit to patients with advanced solid tumors through improved treatment options.
• Collaboration with Genentech (Roche) may strengthen the company's position.

Next Steps

• Continue SON-1010 monotherapy trial in patients with advanced solid tumors.
• Continue Phase 1b/2a dose-escalation study of SON-1010 in combination with atezolizumab for platinum-resistant ovarian cancer.
• Begin trial evaluating dose escalation of SON-1210 in patients with metastatic pancreatic cancer later this calendar year.
• Announce an update on safety at the MTD in the PROC trial in Q1 calendar year 2025.

Key Dates